1. Home
  2. STRO vs RVPH Comparison

STRO vs RVPH Comparison

Compare STRO & RVPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sutro Biopharma Inc.

STRO

Sutro Biopharma Inc.

HOLD

Current Price

$11.82

Market Cap

85.0M

Sector

Health Care

ML Signal

HOLD

Logo Reviva Pharmaceuticals Holdings Inc.

RVPH

Reviva Pharmaceuticals Holdings Inc.

HOLD

Current Price

$0.35

Market Cap

71.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
STRO
RVPH
Founded
2003
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
85.0M
71.0M
IPO Year
2018
N/A

Fundamental Metrics

Financial Performance
Metric
STRO
RVPH
Price
$11.82
$0.35
Analyst Decision
Hold
Strong Buy
Analyst Count
8
7
Target Price
$18.29
$3.14
AVG Volume (30 Days)
101.4K
8.7M
Earning Date
11-06-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$105,646,000.00
N/A
Revenue This Year
$63.08
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.23
$0.25
52 Week High
$21.50
$2.17

Technical Indicators

Market Signals
Indicator
STRO
RVPH
Relative Strength Index (RSI) 75.24 39.14
Support Level $10.15 $0.27
Resistance Level $12.18 $0.34
Average True Range (ATR) 0.93 0.05
MACD -0.19 -0.01
Stochastic Oscillator 85.66 24.46

Price Performance

Historical Comparison
STRO
RVPH

About STRO Sutro Biopharma Inc.

Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.

About RVPH Reviva Pharmaceuticals Holdings Inc.

Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease and Parkinson's disease psychosis and its other drug candidate is RP1208.

Share on Social Networks: